期刊
ADDICTIVE BEHAVIORS
卷 102, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.addbeh.2019.106128
关键词
Alcohol; Abuse; Dependence; Remission; Comorbidity; Prevalence
资金
- United States National Institute of Mental Health (NIMH) [R01 MH070884]
- John D. and Catherine T. MacArthur Foundation
- Pfizer Foundation
- United States Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
- Fogarty International Center [FIRCA R03-TW006481]
- Pan American Health Organization
- Eli Lilly and Company
- Ortho-McNeil Pharmaceutical Inc.
- GlaxoSmithKline
- Bristol-Myers Squibb
- Australian National Health and Medical Research Council (NHMRC) [APP1081984]
- Australian Government Department of Health and Ageing
- Argentinian Ministry of Health (Ministerio de Salud de la Nacion)
- State of Sao Paulo Research Foundation (FAPESP) [03/00204-3]
- Ministry of Health
- National Center for Public Health Protection
- Ministry of Social Protection
- Center for Excellence on Research in Mental Health (CES University)
- Secretary of Health of Medellin
- European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]
- Piedmont Region (Italy)
- Fondo de Investigation Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028]
- Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
- Departament de Salut, Generalitat de Catalunya, Spain
- DIUE de la Generalitat de Catalunya [2017 SGR 452, 2014 SGR 748]
- Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
- Japanese Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF)
- European Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF)
- Israel National Institute for Health Policy and Health Services Research
- National Insurance Institute of Israel
- Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour and Welfare [H13SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006]
- Lebanese Ministry of Public Health
- WHO (Lebanon)
- National Institute of Health/Fogarty International Center [R03 TW006481-01]
- Algorithm
- AstraZeneca
- Benta
- Bella Pharma
- Eli Lilly
- Glaxo Smith Kline
- Lundbeck
- Novartis
- OmniPharma
- Pfizer
- Phenicia
- Servier
- UPO
- National Institute of Psychiatry Ramon de la Fuente [INPRFM-DIES -19 -4280]
- National Council on Science and Technology [CONACyT-G30544-H]
- Pan American Health Organization (PAHO)
- New Zealand Ministry of Health
- Alcohol Advisory Council
- Health Research Council
- WHO (Geneva)
- WHO (Nigeria)
- Federal Ministry of Health, Abuja, Nigeria
- Health & Social Care Research & Development Division of the Public Health Agency
- National Institute of Health of the Ministry of Health of Peru
- Iceland from the EEA Financial Mechanism [PL 0256]
- Liechtenstein from the EEA Financial Mechanism [PL 0256]
- Norway from the EEA Financial Mechanism [PL 0256]
- Norwegian Financial Mechanism
- Polish Ministry of Health
- Champalimaud Foundation
- Gulbenkian Foundation
- Foundation for Science and Technology (FCT)
- US National Institute of Mental Health [R01-MH059575, RO1-MH61905]
- National Institute of Drug Abuse
- South African Department of Health
- University of Michigan
- Regional Health Authorities of Murcia (Servicio Murciano de Salud)
- Regional Health Authorities of Murcia (Consejeria de Sanidad y Politica Social)
- Fundacion para la Formacion e Investigacion Sanitarias (FFIS) of Murcia
- National Institute of Mental Health (NIMH) [U01-MH60220]
- National Institute of Drug Abuse (NIDA)
- Substance Abuse and Mental Health Services Administration (SAMHSA)
- Robert Wood Johnson Foundation (RWJF) [044708]
- John W. Alden Trust
- NHMRC [1135991]
- NIDA NIH grant [R01 DA044170-02]
- Danish National Research Foundation (Niels Bohr Professorship)
- John Cade Fellowship from National Health and Medical Research Council [APP1056929]
Background: Prevalences of Alcohol Use Disorders (AUDs) and Mental Health Disorders (MHDs) in many individual countries have been reported but there are few cross-national studies. The WHO World Mental Health (WMH) Survey Initiative standardizes methodological factors facilitating comparison of the prevalences and associated factors of AUDs in a large number of countries to identify differences and commonalities. Methods: Lifetime and 12-month prevalence estimates of DSM-IV AUDs, MHDs, and associations were assessed in the 29 WMH surveys using the WHO CIDI 3.0. Results: Prevalence estimates of alcohol use and AUD across countries and WHO regions varied widely. Mean lifetime prevalence of alcohol use in all countries combined was 80%, ranging from 3.8% to 97.1%. Combined average population lifetime and 12-month prevalence of AUDs were 8.6% and 2.2% respectively and 10.7% and 4.4% among non-abstainers. Of individuals with a lifetime AUD, 43.9% had at least one lifetime MHD and 17.9% of respondents with a lifetime MHD had a lifetime AUD. For most comorbidity combinations, the MHD preceded the onset of the AUD. AUD prevalence was much higher for men than women. 15% of all lifetime AUD cases developed before age 18. Higher household income and being older at time of interview, married, and more educated, were associated with a lower risk for lifetime AUD and AUD persistence. Conclusions: Prevalence of alcohol use and AUD is high overall, with large variation worldwide. The WMH surveys corroborate the wide geographic consistency of a number of well-documented clinical and epidemiological findings and patterns.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据